Evonik to showcase CYROLITE® polymers for medical devices, expanding applications in blood-contacting area
• CYROLITE® multipolymer compounds are the most highly developed (PMMA) acrylic-based polymers for medical devices
• The material is resistant to alcohol and lipids and is also impact-resistant and transparent
• CMEF - ICMD 2017: Booth No. M68, Hall 6.1
Evonik Industries will present CYROLITE® compounds at this year’s ICMD in Shanghai, China. With a history of biocompatibility, processability, and toughness, the product becomes an excellent candidate for medical devices.
CYROLITE® is based on more than 40 years’ experience in medical and diagnostic applications. Highly transparent and tough, these compounds are specially engineered to support the medical device industry. They are resistant to lipids, alcohol and the plasticizers found in PVC tubing. They can be sterilized with gamma rays, e-beam, and EtO gas and can be processed by all conventional thermoplastic processing methods. All CYROLITE® grades meet the requirements of USP classes 6 and 26, Tripartite, ISO 10993-1 and FDA and are free from Bisphenol A (BPA), Bisphenol S (BPS) and Di-(2-ethylhexyl) phthalate(DEHP).
CYROLITE® is used in a wide variety of medical devices including luer locks, connectors, catheter accessories, Y-sites, filter housings and blood collection devices. This material is not recommended for outdoor or implantable applications. Evonik has also developed different variants of CYROLITE® multipolymer compounds for special applications: CYROLITE® Protect and CYROLITE® Protect 2 are microbe resistant (PMMA) acrylic-based compounds; CYROLITE® MD PMMA is suitable for diagnostic applications; Vu-Stat™ Y-20 for electro-static dissipative medical application.
“Evonik is continuing to devote R&D to our medical area.” says Gren Liu, General Manager for PMMA molding compounds Asia. At the end of 2016, Evonik announced a new finding that suggests CYROLITE® G-20 HIFLO® and Med 2 materials may have qualities that reduce the adhesion and/or activation of human blood platelets when compared to certain other grades of polymers, making them excellent candidates for blood-contacting application.
For more information about the project, please contact Kitty YANG
Tel: +86 21 6119 3038
Mobile: +86 15921547899
Email: kitty.yang@evonik.com
Company information
Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world with more than 35,000 employees. In fiscal 2016 the enterprise generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.
Evonik Industries has been producing specialty chemical products in the Greater China region (Mainland China, Hong Kong and Taiwan) since the late 1970’s; with wide-ranging trading relations already in place prior to this in the region. Evonik regards Greater China as one of the driving forces of the global economy and we consequently endeavor to grow our business in the region. The company now has around 3,000 employees in the Greater China region, the regional sales reached about €1.3 billion in 2016.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.